Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Theresa Ross"'
Autor:
Kyle Pedro, Alonso Villasmil Ocando, Benjamin Primack, Meghan Langley, Theresa Ross, Jeremy Tchaicha, Michelle Ols, Jan ter Meulen, Violet Young, Gauri Kulkarni, Arman Aksoy, Rachel A Burga
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7fe68b97f73249be9b4b5a446cd02a74
Autor:
Gabriel Helmlinger, Rachel Burga, Stanley Tam, Mithun Khattar, Scott Lajoie, Kyle Pedro, Colleen Foley, Alonso Villasmil Ocando, Jack Tremblay, Benjamin Primack, Meghan Langley, Dan Thornton, Emily Brideau, Theresa Ross, Gwen Wilmes, Sunandan Saha, Jeremy Tchaicha, Dhruv Sethi, Michelle Ols, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/96bcf551331a468aa219481d0e648459
Autor:
Sean Smith, Benjamin Primack, Theresa Ross, Patricia Timpug, Dexue Sun, Dan Jun Li, Scott Lajoie, Violet Young, Meghan Langley, Jeremy Tchaicha, Dhruv Sethi, Jan ter Meulen, Michelle Ols
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Rachel Burga, Zheng Ao, Arman Aksoy, Scott Lajoie, Kyle Pedro, Jack Tremblay, Gauri Kulkarni, Alonso Villasmil Ocando, Benjamin Primack, Meghan Langley, Theresa Ross, Jeremy Tchaicha, Michelle Ols, Jan ter Meulen, Mithun Khattar
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Carmela Passaro, Balazs Koscso, Sean Smith, Violet Young, Theresa Ross, Benjamin Primack, Natasha Ly, Patricia Timpug, Shabnam Davoodi, Rachel Burga, Gauri Kulkarni, Scott Lajoie, Meghan Langley, Nirzari Shah, Dexue Sun, Dan Jun Li, Raina Duan, Arman Aksoy, Mithun Khattar, Jeremy Tchaicha, Dhruv Sethi, Jan ter Meulen, Michelle Ols
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Kyle D. Pedro, Rachel Burga, Alonso Villasmil Ocando, Meghan Langley, Gauri Kulkarni, Zheng Ao, Benjamin Primack, Theresa Ross, Violet Young, Jeremy Tchaicha, Michelle Ols, Jan Ter Meulen
Publikováno v:
Cancer Research. 83:LB096-LB096
Tumor infiltrating lymphocyte (TIL) therapy has shown promising results in the treatment of metastatic melanoma. However, TIL therapy has conventionally required co-administration of IL2, which is associated with toxicity in patients. We previously s
Publikováno v:
ACS chemical biology. 17(5)
Ketoreductases (KRs) are canonical domains of type I polyketide synthases (PKSs). They stereoselectively reduce ACP-bound β-ketothioester intermediates and are responsible for a large part of the stereocenters in reduced polyketides. Albeit essentia
Publikováno v:
RSC Advances. 11:20248-20251
The potential of polyketide synthase (PKS) domains for chemoenzymatic synthesis can often not be tapped due to their low stability and activity in vitro. In this proof-of-principle study, the immobilisation of the heterocycle-forming PKS domain AmbDH
Autor:
Sunandan Saha, Rachel A. Burga, Meghan Langley, Michelle Ols, Jack Tremblay, Stanley Tam, Jeremy Hatem Tchaicha, Benjamin Primack, Colleen Foley, Gabriel Helmlinger, Theresa Ross, Sethi Dhruv Kam, Emily Brideau, Shyam Subramanian, Alonso Villasmil Ocando, Kyle Pedro, Mithun Khattar, Scott Lajoie, Gary Vanasse, Dan Thornton, Jan ter Meulen, Gwen Wilmes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated tremendous promise in clinical trials for patients with solid or metastatic tumors.1 However, current TIL therapy requires systemic administration of IL-2 to
Autor:
Jeremy H. Tchaicha, Scott Lajoie, Rachel Burga, Theresa Ross, Benjamin Primack, Meghan Langley, Violet Young, Alonso Villasmil Ocando, Kyle Pedro, Jack Tremblay, Gauri Kulkarni, Mithun Khattar, Dhruv Sethi, Michelle Ols, Gabriel Helmlinger, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Publikováno v:
Cancer Research. 82:LB212-LB212
Standard tumor-infiltrating lymphocyte (TIL) therapy requires IL-2 administration to support TIL expansion and survival, but this cytokine is associated with T cell exhaustion and can result in severe toxicities that limit patient eligibility (1). To